Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase

The clinical availability of small molecule inhibitors specifically targeting mutated BRAF marked a significant breakthrough in melanoma therapy. Despite a dramatic anti-tumour activity and improved patient survival, rapidly emerging resistance, however, greatly limits the clinical benefit. The majo...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncotarget
Prif Awduron: Kosnopfel, Corinna, Sinnberg, Tobias, Sauer, Birgit, Niessner, Heike, Schmitt, Anja, Makino, Elena, Forschner, Andrea, Hailfinger, Stephan, Garbe, Claus, Schittek, Birgit
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Impact Journals LLC 2017
Pynciau:
Research Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5482615/
https://ncbi.nlm.nih.gov/pubmed/28415756
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.16204
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg